← SynDRA
DECERNOTINIB
SynDRA canonical compound SYN0037760 — structure-anchored drug synonym record
| Clinical phase | Phase 2/Phase 3 |
|---|
| Primary target(s) | JAK2 | JAK3 |
|---|
| Mechanism of action | JAK inhibitor | protein tyrosine kinase inhibitor |
|---|
| Indication | rheumatoid arthritis |
|---|
| Disease area | Immunology |
|---|
All known targets
Mechanisms of action (all sources)
- JAK3 INHIBITOR
- Tyrosine-protein kinase JAK3 inhibitor
- JAK1 INHIBITOR
- JAK2 INHIBITOR
- JAK inhibitor
- tyrosine kinase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PRKCB
- CDK17
- CDK9
- CSNK2A2
- JAK1
- MAP3K2
- ABL1
- MARK2
- MARK3
- MET
- PKN1
- PLK4
- PRKACA
- PRKCA
- PRKCD
- CDC42BPA
- ROCK1
- ROCK2
- SLK
- STK10
- STK26
- SYK
- TAOK1
- TAOK3
- TNK1
- TOP2A
- TOP2B
- TP53RK
- TYK2
- CDC42BPB
- YJ005
- ABL2
- BMP2K
- CAMK2D
- ARAF
- PRKACB
- AKT3
- PRKAA1
- APRT
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP2D6
- CP3A7
- HLA-B
- HLAB
- IFNB1
- KAPCA
- KSYK
Cross-references
Synonyms
- Adelatinib
- VRT-831509
- VX-509
- VX 509
- UNII-MZK2GP0RHK
- Decernotinib(VX-509)
- VX509
- MZK2GP0RHK
- VRT 831509
- (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide
- (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide
- Decernotinib [USAN:INN]
- Decernotinib,VX-509
- Decernotinib (USAN/INN)
- Decernotinib (VX-509)
- VX-509 (Decernotinib)
- SCHEMBL2630387
- GTPL8309
- CHEMBL3039513
- KS-00001CYK
- decernotinibum
- RefChem:407157
- DTXCID30163995
- Decernotinib (VX-509,adelatinib)
- C18H19F3N6O
- MFCD27987896
- DECERNOTINIB [INN]
- DECERNOTINIB [USAN]
- DECERNOTINIB [WHO-DD]
- orb1305235
- SCHEMBL29349797
- SCHEMBL29393666
- GLXC-90220
- Decernotinib; Adelatinib; VX-509
- EX-A1580
- BDBM50021655
- NSC800088
- s7541
- AKOS025290739
Look up DECERNOTINIB in the interactive SynDRA portal →